Dubai Telegraph - Tests of HIV vaccine using mRNA technology have begun

EUR -
AED 3.843685
AFN 77.423228
ALL 98.991341
AMD 412.46392
ANG 1.886635
AOA 958.556336
ARS 1108.465738
AUD 1.646152
AWG 1.883625
AZN 1.783134
BAM 1.955629
BBD 2.113615
BDT 127.188874
BGN 1.958046
BHD 0.394166
BIF 3100.228812
BMD 1.046458
BND 1.399278
BOB 7.233367
BRL 5.998828
BSD 1.046808
BTN 90.393093
BWP 14.40974
BYN 3.4259
BYR 20510.585864
BZD 2.102816
CAD 1.489686
CDF 3003.336166
CHF 0.939704
CLF 0.025745
CLP 987.943581
CNY 7.587913
CNH 7.589571
COP 4267.526704
CRC 528.753748
CUC 1.046458
CUP 27.731149
CVE 110.255356
CZK 25.074509
DJF 186.413694
DKK 7.460835
DOP 65.234294
DZD 141.056661
EGP 52.899373
ERN 15.696877
ETB 131.860866
FJD 2.401313
FKP 0.827646
GBP 0.828517
GEL 2.934124
GGP 0.827646
GHS 16.252578
GIP 0.827646
GMD 75.345381
GNF 9051.208258
GTQ 8.079293
GYD 219.600791
HKD 8.131035
HNL 26.759659
HRK 7.537226
HTG 137.397981
HUF 403.295032
IDR 17059.470501
ILS 3.732236
IMP 0.827646
INR 90.674841
IQD 1371.38004
IRR 44042.824533
ISK 145.751138
JEP 0.827646
JMD 165.145554
JOD 0.742153
JPY 156.16827
KES 135.618137
KGS 91.513195
KHR 4199.632643
KMF 492.362677
KPW 941.818353
KRW 1503.48354
KWD 0.32299
KYD 0.872424
KZT 529.363695
LAK 22740.010848
LBP 93743.89988
LKR 309.492928
LRD 208.841732
LSL 19.20112
LTL 3.08992
LVL 0.632993
LYD 5.115553
MAD 10.421088
MDL 19.534291
MGA 4950.566956
MKD 61.524618
MMK 2196.437436
MNT 3626.32255
MOP 8.378667
MRU 41.884336
MUR 48.430494
MVR 16.119373
MWK 1815.241214
MXN 21.38365
MYR 4.623781
MZN 66.872598
NAD 19.20112
NGN 1572.053084
NIO 38.52663
NOK 11.664981
NPR 144.629349
NZD 1.822622
OMR 0.402655
PAB 1.046808
PEN 3.855663
PGK 4.274626
PHP 60.565357
PKR 292.589906
PLN 4.162446
PYG 8260.277443
QAR 3.815966
RON 4.979158
RSD 117.189749
RUB 93.091857
RWF 1473.071145
SAR 3.924399
SBD 8.824657
SCR 15.046684
SDG 628.921891
SEK 11.146984
SGD 1.39734
SHP 0.831543
SLE 23.796854
SLL 21943.716629
SOS 598.247669
SRD 37.215242
STD 21659.577382
SVC 9.160199
SYP 13606.033167
SZL 19.195321
THB 35.122325
TJS 11.410502
TMT 3.662605
TND 3.31001
TOP 2.450914
TRY 38.036712
TTD 7.113378
TWD 34.31132
TZS 2706.063291
UAH 43.564289
UGX 3843.663781
USD 1.046458
UYU 45.206046
UZS 13520.817285
VES 66.273192
VND 26710.852255
VUV 129.071619
WST 2.940274
XAF 655.899626
XAG 0.032128
XAU 0.000356
XCD 2.828107
XDR 0.79883
XOF 655.899626
XPF 119.331742
YER 258.792935
ZAR 19.231085
ZMK 9419.385666
ZMW 29.49442
ZWL 336.959198
  • BCC

    -9.4800

    107

    -8.86%

  • SCS

    -0.1200

    12.31

    -0.97%

  • NGG

    0.2100

    61.31

    +0.34%

  • GSK

    0.0807

    36.64

    +0.22%

  • CMSD

    -0.0500

    23.42

    -0.21%

  • BTI

    -0.7000

    37.85

    -1.85%

  • RBGPF

    65.4200

    65.42

    +100%

  • AZN

    0.7100

    74.22

    +0.96%

  • BCE

    0.4000

    23.97

    +1.67%

  • RIO

    -0.7600

    63.53

    -1.2%

  • RYCEF

    -0.1300

    7.7

    -1.69%

  • VOD

    0.1000

    8.36

    +1.2%

  • CMSC

    -0.0300

    23.37

    -0.13%

  • RELX

    -1.1200

    49.29

    -2.27%

  • JRI

    -0.0200

    12.8

    -0.16%

  • BP

    -0.2800

    33.89

    -0.83%

Tests of HIV vaccine using mRNA technology have begun
Tests of HIV vaccine using mRNA technology have begun

Tests of HIV vaccine using mRNA technology have begun

Testing in humans of an HIV vaccine that uses messenger RNA technology has begun, the biotech firm Moderna and the International AIDS Vaccine Initiative said Thursday.

Text size:

This Phase 1 trial is being carried out in the United States among 56 healthy adults who are HIV negative.

Despite four decades of research, doctors have yet to develop a vaccine to protect people from the virus that causes AIDS, which kills hundreds of thousands of people around the world each year.

But hopes have been stirred with the success of mRNA technology, which allowed for the development of Covid-19 vaccines in record time, including one from Moderna.

The goal of the vaccine now being tested is to stimulate production of a kind of antibody called "broadly neutralizing antibodies," or bnAbs, which can act against the many variants of HIV that are circulating today.

The vaccine is supposed to teach B lymphocytes, which are part of the immune system, to generate these antibodies.

In this trial, participants are injected with an immunogen -- a substance that can trigger an immune response -- and then a booster immunogen later.

These substances will be delivered with mRNA technology.

"The induction of bnAbs is widely considered to be a goal of HIV vaccination, and this is the first step in that process," Moderna and the IAVI, a research organization, said in a statement.

"Further immunogens will be needed to guide the immune system on this path, but this prime-boost combination could be the first key element of an eventual HIV immunization regimen," said David Diemert, a lead investigator at one of the four sites where the trial is being carried out, George Washington University in the US capital.

The immunogens used in this trial were developed by IAVI and the Scripps Research Institute, with support from the Bill & Melinda Gates Foundation, the US National Institute of Allergy and Infectious Diseases and Moderna.

A first trial last year tested the first immunogen but without employing mRNA technology. It showed that the desired immune response was triggered in dozens of people taking part in the research.

The next step was to bring in Moderna with its new mRNA technique.

"Given the speed with which mRNA vaccines can be produced, this platform offers a more nimble and responsive approach to vaccine design and testing," the Moderna-IAVI statement said.

"The search for an HIV vaccine has been long and challenging, and having new tools in terms of immunogens and platforms could be the key to making rapid progress toward an urgently needed, effective HIV vaccine," said Mark Feinberg, the CEO of IAVI.

A.El-Nayady--DT